XENOGRAFT
EFFICACY STUDIES
U.S.-Based Xenograft CRO
DOMESTIC QUALITY. EXCEPTIONAL VALUE.
Rincon conducts studies at our U.S. facilities: keeping your work close, your IP protected, and communication direct. We bring the depth of expertise you’d expect from a major CRO without the administrative layers and overhead. That means more of your budget goes directly toward the science.
DIRECT ACCESS
Work directly with the PhD running your study—not a rotating account manager. We stay responsive, flexible, and hands-on throughout the study.
Rincon provides custom xenograft study services using human tumor models in immunocompromised mice and rats.
We can work from your existing protocol or help develop a study design around your model, compound, and research objectives.
Our experienced team runs studies at our U.S.-based facilities with direct scientific oversight, fast initiation, and the flexibility to adjust when the data calls for it.
Additional capabilities include:
-
Custom xenograft study designs
-
Fluorescent and luminescent imaging
-
MTD and tolerability studies
-
Preclinical drug formulation
-
Tumor and organ collection
-
Histology and animal pathology
-
Pharmacodynamic assays including ELISA, Mesoscale/Luminex, PCR, sequencing, and flow cytometry
-
Complementary cell-based in vitro assays supporting in vivo studies
Please see below for our available models or to request a quote
XENOGRAFT
cell lines
Cell line | Organ | Mutations | Weeks from stratification to termination (average) | Growth Curve |
|---|---|---|---|---|
22Rv1 | Prostate | KMT2D, PIK3CA, TP53 | 5 | |
786-0 | Renal | PTEN, TERT, TP53, VHL | N/A | |
A-375 | Skin | BRAF, CDKN2A, TERT | 4 | |
A431 | Skin | TP53, EGFR-PPARGC1A fussion | N/A | |
A498 | Renal | PIK3CB, VHL | 5 | |
A549 | Lung | KRAS, STK11, TP53 | 6 | |
A673 | Sarcoma | BRAF, TP53, EWS-FLI1 fusion | 3 | |
AGS | Gastric | CTNNB1, KRAS, PIK3CA, TP53 | 6 | |
BxPc-3 | Pancreatic | BRAF, KRAS, TP53 | 7 | |
CHLA-06 | Brain | TP53 | 6 | |
Caki-1 | Renal | RB1 | 4 | |
Colo-205 | Colon | APC, BRAF, CTNNB1, TP53 | 2.5 | |
DLD-1 | Colon | APC, ACVR2A, B2M, EP300, KRAS, PIK3CA, TGFBR2, TP53 | 4 | |
DU-145 | Prostate | CDKN2A, RB1, STK11, TP53 | 6 | |
ES-2-luc | Ovarian | BRAF, PALB2, TERT, TP53 | 3.5 | |
HCC1954 | Breast | PIK3CA, TP53, CLTC-VMP1 fusion | 7 | |
HCT-116 | Colon | ACVR2A, BRCA2, CDKN2A, CTNNB1, EP300, KRAS, PIK3CA, PPM1D, TGFBR2, TP53 | 5 | |
HT-29 | Colon | APC, BRAF, PIK3CA, SMAD4, TP53 | N/A | |
HuCCT1 | Bile Duct | KRAS, MSH6, TP53 | 5 | |
Huh-7 | Liver | KDR, POLD3, TERT, TP53 | 4 | |
JIMT-1 | Breast | PIK3CA, TP53 | 8 | |
JeKo-1 | Blood | TP53 | 5 | |
LASCPC-01 | Prostate | Unavailable | 3 | |
LNCaP | Prostate | AR, MEN1, PIK3R1, PTEN, TP53 | 4 | |
MDA-MB-231 | Breast | CDKN2A, CDKN2B, BRAF, KRAS, TERT, TP53 | 4 | |
MDA-MB-468 | Breast | PTEN, RB1, TP53 | N/A | |
MIAPaCa-2 | Pancreatic | KRAS, TP53 | 8 | |
MOLM-13 | Blood | FLT3, KMT2A-MLLT3 fusion | 14 | |
NCI-H1703 | Lung | CDKN2A, TP53 | 3 | |
NCI-H1975 | Lung | EGFR, PIK3CA, TP53 | 6 | |
NCI-H460 | Lung | KRAS, PIK3CA, STK11, TP53 | 5 | |
NCI-N87 | Gastric | ERBB3, TP53 | 6 | |
OCI-AML-3 | Blood | DNMT3A, NRAS, NPM1 | 2 | |
OCI-Ly1 | Blood | Unavailable | N/A | |
OVCAR8 | Ovarian | CTNNB1, ERBB2, KRAS, TP53 | 8 | |
PANC-1 | Pancreatic | KRAS, TP53 | 3 | |
PC-3 | Prostate | TP53 | 4 | |
SK-BR-3 | Breast | TP53 | 4 | |
SK-N-FI | Brain | NF1, TP53 | 4 | |
SK-N-MC | Sarcoma | TP53, EWS-FLI1 fusion | 3 | |
SK-OV-3 | Ovarian | APC, FBXW7, PIK3CA, TP53 | 10 | |
SKM-1 | Blood | ASXL1, BCORL1, EZH2, KRAS, TP53 | 3 | |
SU-DHL-16 | Blood | Unavailable | 4 | |
SW480 | Colon | APC, KRAS, TP53 | 4 | |
TT | Thyroid | RET, TBX3 | 4 | |
U-87MG | Brain | Unavailable | 3 | |
U118-MG | Brain | IDH1, PTEN, TP53 | 6 | |
UM-UC-3 | Bladder | KRAS, PARD3B, TERT, TP53 | N/A | |
VcAP | Prostate | MLH1, TP53, TMPRss2-ERG fusion | N/A | |
WITT (SK-Cha-1) | Bile Duct | Unavailable | N/A | |
WM164 | Skin | BRAF | 6 | |
YAPC | Pancreatic | KRAS, TP53 | N/A |
Don't see your model? Additional cell lines and custom models are possible. Contact us to discuss your study.
QUOTE REQUEST FORM
xenograft studies
Share as much information as you currently have.
Preliminary study details are fine.
We will respond with a quote within one business day
MEET OUR SCIENTIFIC DIRECTOR
Bret Stephens, PhD
Bret brings more than 20 years of in vivo biology and cancer drug-discovery experience spanning pharmaceutical and academic research.
At Rincon, Bret remains directly involved in study design and execution—part of our approach of giving clients direct access to the scientists responsible for their work.
Dr. Stephens received his PhD in Molecular Biology from the University of Arizona.
Previous to joining Rincon Bio, Dr. Stephens worked at Tolero Pharmaceuticals, Huntsman Cancer Institute (University of Utah), and the BioDesign Institute (Arizona State University), where he focused on cancer small molecule drug development.
ABOUT US
We built Rincon around a few things we think matter: strong science, exceptional value, rapid study initiation, and direct access to the people doing the work.
We’ve worked in pharma, academia, and major CROs, so we’ve seen both what works and what gets in the way. Rincon keeps the focus where it belongs: experienced scientists, well-run studies, and useful data.
We specialize in xenograft and syngeneic cancer models, and our team brings experience from thousands of in vivo studies for biotech, pharmaceutical, and academic groups around the world. We stay close to the work and keep the process straightforward from study design through final report.
We’re not trying to be the biggest CRO. We’re aiming to be the one you want to work with.
Email: info@rinconbio.com
Tel: 760-713-6613
Utah:
3900 N Traverse Mountain Blvd
Suite 100
Lehi, UT 84043
California:
3156 Vista Way, Suite 220
Oceanside, CA 92056